Reversine (SKU A3760): Aurora Kinase Inhibitor Workflow Guide

This practical guide is based on the supplied product dossier and general laboratory workflow principles. No directly matched paper evidence was supplied for this article, so the product values below should be treated as dossier specifications rather than as independently verified performance data in a particular cell line or animal model. The APExBIO product page for Reversine identifies the compound as 6-N-cyclohexyl-2-N-(4-morpholin-4-ylphenyl)-7H-purine-2,6-diamine, supplied as a solid for research use.

What This Product Solves

Reversine is useful when an experiment requires pharmacological perturbation of Aurora kinase signaling pathway activity during mitotic progression. The dossier identifies Aurora kinase A, B, and C as targets, with reported biochemical IC₅₀ values of 150 nM, 500 nM, and 400 nM, respectively. These values establish a target-level reference point; they do not define the concentration required to produce a cellular phenotype.

In a cancer biology workflow, the compound can support studies of mitotic checkpoint control, cell-cycle regulation, cancer cell proliferation inhibition, and apoptosis induction in cancer cells. The dossier also describes in vitro dedifferentiation of murine myoblasts and anti-tumor observations in murine cervical cancer models. Those descriptions can help select experimental questions, but they should not be interpreted as proof that the same response will occur in an untested cell line, culture condition, or animal model.

For a broader product-focused background, Reversine as an Aurora Kinase Inhibitor: Technical Guidance complements this article by summarizing research-use positioning and mitotic-regulation applications. For pathway-oriented context, Reversine: Unraveling Aurora Kinase Pathways in Cancer Cells provides related discussion of checkpoint and apoptosis study design.

Protocol Parameters

The following entries separate product specifications from workflow recommendations. Use the biochemical values for planning and comparison, not as direct cellular dosing instructions. Confirm the actual concentration range in a pilot experiment using the selected model and endpoint.

Protocol Parameters

• Assay: Aurora kinase A inhibition; Value: 150 nM IC₅₀; Applicability: biochemical target reference; Rationale: supports initial concentration-range planning for Aurora A-focused assays; Source type: product specification.
• Assay: Aurora kinase B inhibition; Value: 500 nM IC₅₀; Applicability: biochemical target reference; Rationale: provides a separate benchmark when interpreting mitotic or chromosome-segregation phenotypes; Source type: product specification.
• Assay: Aurora kinase C inhibition; Value: 400 nM IC₅₀; Applicability: biochemical target reference; Rationale: indicates that Aurora C should be considered when assigning pathway-level effects; Source type: product specification.
• Assay: DMSO solubility check; Value: at least 19.65 mg/mL; Applicability: stock-solution preparation; Rationale: DMSO is the primary solvent identified for preparing a concentrated laboratory stock; Source type: product specification.
• Assay: Ethanol solubility check; Value: at least 6.69 mg/mL with gentle warming and ultrasonic treatment; Applicability: alternative stock preparation; Rationale: use only when the study permits ethanol and verify clarity after treatment; Source type: product specification.
• Assay: Material storage; Value: −20 °C; Applicability: unopened solid and routine material storage; Rationale: follows the stated storage condition, while prepared solutions should not be retained long term; Source type: product specification.

Workflow Setup and QC Checklist

Prepare the compound

1. Inspect the solid container, confirm the identity and SKU against the study record, and allow the container to equilibrate only as needed to reduce condensation during handling. Minimize repeated warming and opening.
2. Because Reversine is insoluble in water, select DMSO or, where scientifically appropriate, ethanol as the stock solvent. Calculate the required stock concentration from the weighed mass and recorded molecular information rather than estimating from the intended treatment concentration.
3. Add solvent gradually, mix thoroughly, and inspect the solution against a clean solvent blank. If ethanol is used, apply only gentle warming and ultrasonic treatment as stated in the dossier. Do not proceed with visible particles, persistent haze, or material adhering to the vessel.
4. Prepare fresh working dilutions close to the treatment step. Keep the final solvent concentration consistent across all treated and control conditions. Avoid assuming that a clear stock remains stable after prolonged storage; the dossier does not recommend long-term storage of solutions.

Design the assay

• Define the primary endpoint before treatment. Suitable study categories include cell number or viability, cell-cycle distribution, mitotic morphology, kinase-pathway readouts, and apoptosis-related measurements. Pair a broad phenotypic endpoint with an orthogonal readout whenever possible.
• Use a concentration series that brackets the expected biological response rather than treating the biochemical IC₅₀ as a guaranteed cellular effective concentration. Include untreated and vehicle controls, and keep plating density, solvent exposure, and treatment duration matched.
• For cancer cell proliferation inhibition studies, confirm that reduced signal is not caused by precipitation, solvent toxicity, evaporation, or baseline differences in cell density. For apoptosis induction in cancer cells, measure an apoptosis-related endpoint alongside a general viability readout.
• In cervical cancer research, record the exact cell-line passage range, culture medium, seeding conditions, and treatment schedule. Differences among cervical cancer cell lines can alter baseline proliferation and apparent drug response.

QC checklist

• Verify stock clarity and document solvent, preparation date, handling conditions, and storage history.
• Confirm that vehicle-only wells retain expected morphology and viability.
• Check assay linearity over the selected cell-density range before interpreting treatment effects.
• Review raw images or well-level measurements for edge effects, contamination, uneven seeding, and precipitation.
• Repeat key findings in an independent experiment and report the actual concentration, exposure conditions, and normalization method.

Common Failure Modes and Fixes

Visible precipitation after dilution

Rapid dilution into aqueous medium can exceed the compound’s local solubility and produce particles that create false cytotoxicity or uneven dosing. Prepare a compatible intermediate dilution, add it slowly with mixing, and inspect the final medium. If precipitation persists, reduce the stock-to-medium transfer burden, reassess the solvent, and repeat a solubility check before collecting biological data.

Vehicle-related toxicity

DMSO or ethanol can affect membrane integrity, proliferation, and assay signals independently of Reversine. Match the vehicle in every treatment and control condition, keep the solvent burden as low as practical, and confirm vehicle tolerance in the same cell type and assay format.

Overinterpreting biochemical potency

An IC₅₀ from a kinase assay does not account for cellular uptake, protein binding, efflux, metabolism, or the time required to produce a phenotype. Use the dossier values to organize a pilot range, then report the observed cellular response independently from the biochemical reference.

Using a single endpoint

A lower viability signal alone cannot distinguish slowed proliferation, mitotic failure, nonspecific toxicity, or apoptosis. Add cell-cycle, morphology, or apoptosis-related measurements that are appropriate for the model and avoid assigning a mechanism that was not directly measured.

Uncontrolled combination experiments

The dossier describes enhanced effects in murine cervical cancer models when Reversine was combined with aspirin. This is not a universal combination protocol. If a combination is studied, include each single agent, the vehicle controls, and a predefined analysis plan so that apparent synergy is not confused with additive toxicity or unequal solvent exposure.

Scope and Limitations

This article is a dossier-based planning resource, not a substitute for matched literature validation. The reported Aurora kinase A, B, and C values are useful reference points but do not establish selectivity, intracellular target engagement, or a reproducible cellular dose across models. The dossier’s in vitro and in vivo descriptions should therefore be treated as context for hypothesis generation and experimental design, not as guaranteed outcomes.

Do not extrapolate results from murine myoblasts or murine cervical cancer models directly to human cells, primary cultures, organoids, or clinical settings. No dosing schedule, pharmacokinetic profile, toxicity limit, or validated combination regimen is provided here. Animal work requires institutional approval, model-specific dose justification, and appropriate welfare procedures. Reversine is supplied for scientific research only and is not intended for diagnostic, therapeutic, or medical use.

Conclusion

Reversine (SKU A3760) is best used as a controlled small-molecule perturbagen for experiments involving Aurora kinase biology, mitotic regulation, cell-cycle behavior, and cancer-related phenotypes. Start with the product-defined target and solubility parameters, prepare fresh and visibly clear solutions, match vehicle conditions, and separate biochemical potency from cellular response. Careful controls and orthogonal readouts are essential when interpreting cancer cell proliferation inhibition or apoptosis-related findings in a new model.